The main purpose of this study is to compare the amount of mirikizumab that gets into the
blood stream and how long it takes the body to get rid of it, when given as a solution
formulation via manual prefilled syringe or autoinjector. The information about any adverse
effects experienced will be collected and the tolerability of mirikizumab will also be
evaluated.
Screening is required within 28 days prior to the start of the study. For each participant,
the total duration of the clinical trial will be about 17 weeks, including screening.